<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04227678</url>
  </required_header>
  <id_info>
    <org_study_id>2019-2764</org_study_id>
    <nct_id>NCT04227678</nct_id>
  </id_info>
  <brief_title>Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency</brief_title>
  <acronym>AGL12</acronym>
  <official_title>Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut de Recherches Cliniques de Montreal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lipoprotein lipase (LPL) is an enzyme that plays an important role in removing triglycerides
      (TG) (molecules that transport dietary fat) from the blood. Patients with LPL deficiency
      (LPLD) display during their whole life very high plasma TG levels often associated with
      episodes of postprandial abdominal pain, malaise, blurred vision, dizziness
      (hyperchylomicronemia syndrome) that may lead to recurrent pancreatitis episodes. Because of
      their very slow clearance in blood of their chylomicron-TG, these patients need to severely
      restrict their dietary fat intake to avoid these complications. Fortunately, novel treatments
      are being developed to circumvent LPL deficiency (LPLD) metabolic effect on chylomicron-TG
      clearance. However, there is no data on how LPLD affect organ-specific dietary fatty acid
      metabolism nor how the novel therapeutic agents may change this metabolism. For example, it
      is currently not understood how subjects with LPLD store their DFA into adipose tissues and
      whether they are able to use DFA as a fuel to sustain their cardiac metabolism, as healthy
      individuals do. This study aims to better understand theses two questions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study protocol includes 3 visits: the screening visit and 2 postprandial metabolic
      studies performed in random order at an interval of 7 to 14 days, and performed with (A1) and
      without (A0) an intravenous (i.v.) heparin bolus followed by 250 IU/h i.v during 6 hours.
      Each metabolic study will last 9 hours (with 6 hours postprandial) and will include PET and
      stable isotopic tracer methods. At time 0, a low fat liquid meal will be ingested over 20
      minutes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Organ-specific Dietary Fatty Acid (DFA) partitioning</measure>
    <time_frame>2 months</time_frame>
    <description>will be determined using oral administration of [18F ]-Fluoro‐6‐Thia‐ Heptadecanoic Acid (FTHA ) during whole-body acquisition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial DFA uptake</measure>
    <time_frame>2 months</time_frame>
    <description>will be assessed using oral administration of [18F]-FTHA during dynamic PET acquisition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial nonesterified fatty acids (NEFA) metabolism</measure>
    <time_frame>2 months</time_frame>
    <description>will be determined using [11C]-palmitate during dynamic PET acquisition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary fatty acid oxidation rate</measure>
    <time_frame>6 months</time_frame>
    <description>will be measured using breath [13C]-carbon dioxide enrichment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total oxidation rate</measure>
    <time_frame>2 months</time_frame>
    <description>will be determined by indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postprandial plasma NEFA turnover</measure>
    <time_frame>6 months</time_frame>
    <description>will be determined using stable isotope tracers of fatty acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postprandial plasma glucose turnover</measure>
    <time_frame>6 months</time_frame>
    <description>will be determined using stable isotope tracers of glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular function by Positron Emitting Positron (PET) ventriculography</measure>
    <time_frame>2 months</time_frame>
    <description>will be determined using [11C]-acetate PET/CT. 180 megabecquerel (MBq) will be administered by bolus injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial oxidative metabolism</measure>
    <time_frame>2 months</time_frame>
    <description>will be determined using i.v. [11C]-acetate during dynamic PET/CT scanning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>6 months</time_frame>
    <description>will be determined using a multiplex ELISA which will measure multiple analytes in a single experiment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver nonesterified fatty acids (NEFA) metabolism</measure>
    <time_frame>2 months</time_frame>
    <description>will be determined using [11C]-palmitate during dynamic PET acquisition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolites distribution in plasma</measure>
    <time_frame>2 months</time_frame>
    <description>will be determined using oral administration of [18F]-FTHA</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Lipoprotein Lipase Deficiency</condition>
  <arm_group>
    <arm_group_label>Control group- A0</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control group: Healthy subjects with fasting glucose &lt; 5.6, 2-hour post 75g Oral Glucose Tolerance Test (OGTT) glucose &lt; 7.8 mmol/l and HbA1c &lt; 5.8%; fasting TG &lt; 1.5 mmol/l);
A0: without heparin administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LPLD group-A0</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>LPLD group: LPL deficient subjects with history of fasting TG &gt; 5 mmol/l and homozygote or compound heterozygote for a LPL-gene mutation;
A0: without heparin administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group-A1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control group: Healthy subjects with fasting glucose &lt; 5.6, 2-hour post 75g OGTT glucose &lt; 7.8 mmol/l and HbA1c &lt; 5.8%; fasting TG &lt; 1.5 mmol/l);
A1: with an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours starting 15 minutes before ingestion of liquid meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LPLD group-A1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>LPLD group: LPL deficient subjects with history of fasting TG &gt; 5 mmol/l and homozygote or compound heterozygote for a LPL-gene mutation;
A1: with an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours starting 15 minutes before ingestion of liquid meal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours, starting 15 minutes before ingestion of liquid meal</description>
    <arm_group_label>Control group-A1</arm_group_label>
    <arm_group_label>LPLD group-A1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>liquid meal</intervention_name>
    <description>low fat meal: (500 mL, 898 Kcal, 13% fat, 20.3% protein and 62.3% carbohydrates) will be ingested over 20 minutes</description>
    <arm_group_label>Control group- A0</arm_group_label>
    <arm_group_label>Control group-A1</arm_group_label>
    <arm_group_label>LPLD group-A0</arm_group_label>
    <arm_group_label>LPLD group-A1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  8 healthy LPL-deficient individuals (LPLD subjects) with history of fasting TG &gt; 5
             mmol/l and homozygote or compound heterozygote for a LPL-gene mutation;

          -  8 control subjects (fasting glucose &lt; 5.6, 2-hour post 75g OGTT glucose &lt; 7.8 mmol/l
             and HbA1c &lt; 5.8%; fasting TG &lt; 1.5 mmol/l);

          -  age 18 to 75 yo;

          -  To be willing and able to adhere to the specifications of the protocol;

          -  To have signed an informed consent document indicating that they understood the
             purpose

        Exclusion Criteria:

          -  age &lt; 18 yo;

          -  overt cardiovascular disease as assessed by medical history, physical exam, and
             abnormal ECG

          -  Treatment with a fibrate, thiazolidinedione, beta-blocker or other drug known to
             affect lipid or carbohydrate metabolism (except statins, metformin, and other
             antihypertensive agents that can be safely interrupted);

          -  Treatment with anti-hypertensive medication (only for LPL-deficient individuals);

          -  presence of liver or renal disease; uncontrolled thyroid disorder;

          -  previous diagnosis of heparin-induced thrombocytopenia;

          -  Treatment with oral anticoagulation medication or platelet aggregation inhibiting
             drugs;

          -  A history of major hemorrhagic event;

          -  smoking (&gt;1 cigarette/day) and/or consumption of &gt;2 alcoholic beverages per day;;

          -  Female of child-bearing potential who is pregnant, breast feeding or intends to become
             pregnant or pre-menopausal female with a positive serum pregnancy test at the time of
             enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André Carpentier</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frédérique Frisch</last_name>
    <phone>819-346-1110- ext12394</phone>
    <email>frederique.frisch@usherbrooke.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre de recherche du CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique Frisch</last_name>
      <phone>819-346-1110- ext12394</phone>
      <email>frederique.frisch@usherbrooke.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>André Carpentier</investigator_full_name>
    <investigator_title>tenured professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type I</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

